AUTHOR=Li Shiyong , Xue Junyu , Jiang Ke , Chen Yulu , Zhu Lefan , Liu Rengyun 

TITLE=TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1325345

DOI=10.3389/fonc.2024.1325345

ISSN=2234-943X

ABSTRACT=<p>The telomerase reverse transcriptase (TERT) is overexpressed and associated with poor prognosis in papillary thyroid cancer (PTC), the most common subtype of thyroid cancer. The overexpression of TERT in PTC was partially attributed to transcriptional activation by two hotspot mutations in the core promoter region of this gene. As one of the major epigenetic mechanisms of gene expression regulation, DNA methylation has been proved to regulate several tumor-related genes in PTC. However, the association of <italic>TERT</italic> promoter DNA methylation with TERT expression and PTC progression is still unclear. By treating PTC cell lines with demethylating agent decitabine, we found that the <italic>TERT</italic> promoter methylation and the genes’ expression were remarkably decreased. Consistently, PTC patients with <italic>TERT</italic> hypermethylation had significantly higher TERT expression than patients with <italic>TERT</italic> hypomethylation. Moreover, <italic>TERT</italic> hypermethylated patients showed significant higher rates of poor clinical outcomes than patients with <italic>TERT</italic> hypomethylation. Results from the cox regression analysis showed that the hazard ratios (HRs) of <italic>TERT</italic> hypermethylation for overall survival, disease-specific survival, disease-free interval (DFI) and progression-free interval (PFI) were 4.81 (95% CI, 1.61-14.41), 8.28 (95% CI, 2.14-32.13), 3.56 (95% CI, 1.24-10.17) and 3.32 (95% CI, 1.64-6.71), respectively. The HRs for DFI and PFI remained significant after adjustment for clinical risk factors. These data suggest that promoter DNA methylation upregulates TERT expression and associates with poor clinical outcomes of PTC, thus holds the potential to be a valuable prognostic marker for PTC risk stratification.</p>